Literature DB >> 23544938

Central pathology review for phase III clinical trials: the enabling effect of virtual microscopy.

Pawel Mroz1, Anil V Parwani, Piotr Kulesza.   

Abstract

CONTEXT: Central pathology review (CPR) was initially designed as a quality control measure. The potential of CPR in clinical trials was recognized as early as in the 1960s and quickly became embedded as an integral part of many clinical trials since.
OBJECTIVE: To review the current experience with CPR in clinical trials, to summarize current developments in virtual microscopy, and to discuss the potential advantages and disadvantages of this technology in the context of CPR. DATA SOURCES: A PubMed (US National Library of Medicine) search for published studies was conducted, and the relevant articles were reviewed, accompanied by the authors' experience at their practicing institution.
CONCLUSIONS: The review of the available literature strongly suggests the growing importance of CPR both in the clinical trial setting as well as in second opinion cases. However, the currently applied approach significantly impedes efficient transfer of slides and patient data. Recent advances in imaging, digital microscopy, and Internet technologies suggest that the CPR process may be dramatically streamlined in the foreseeable future to allow for better diagnosis and quality assurance than ever before. In particular, whole slide imaging may play an important role in this process and result in a substantial reduction of the overall turnaround time required for slide review at the central location. Above all, this new approach may benefit the large clinical trials organized by oncology cooperative groups, since most of those trials involve complicated logistics owing to enrollment of large number of patients at several remotely located participating institutions.

Entities:  

Mesh:

Year:  2013        PMID: 23544938     DOI: 10.5858/arpa.2012-0093-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  9 in total

Review 1.  Morphology in the Digital Age: Integrating High-Resolution Description of Structural Alterations With Phenotypes and Genotypes.

Authors:  Cynthia C Nast; Kevin V Lemley; Jeffrey B Hodgin; Serena Bagnasco; Carmen Avila-Casado; Stephen M Hewitt; Laura Barisoni
Journal:  Semin Nephrol       Date:  2015-05       Impact factor: 5.299

2.  The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading.

Authors:  O Pozdnyakova; S Rodig; S Bhandarkar; K Wu; J Thiele; R Hasserjian
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

Review 3.  Digital pathology in nephrology clinical trials, research, and pathology practice.

Authors:  Laura Barisoni; Jeffrey B Hodgin
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-11       Impact factor: 2.894

4.  The use of digital pathology and image analysis in clinical trials.

Authors:  Robert Pell; Karin Oien; Max Robinson; Helen Pitman; Nasir Rajpoot; Jens Rittscher; David Snead; Clare Verrill
Journal:  J Pathol Clin Res       Date:  2019-03-25

5.  Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and meta-aggregation.

Authors:  Shujing Jane Lim; Kurinchi Gurusamy; Daniel O'Connor; Abeer M Shaaban; Daniel Brierley; Ian Lewis; David Harrison; Timothy James Kendall; Max Robinson
Journal:  J Pathol Clin Res       Date:  2021-02-26

Review 6.  Digital pathology and artificial intelligence in translational medicine and clinical practice.

Authors:  Vipul Baxi; Robin Edwards; Michael Montalto; Saurabh Saha
Journal:  Mod Pathol       Date:  2021-10-05       Impact factor: 7.842

7.  Dissecting the Business Case for Adoption and Implementation of Digital Pathology: A White Paper from the Digital Pathology Association.

Authors:  Giovanni Lujan; Jennifer C Quigley; Douglas Hartman; Anil Parwani; Brian Roehmholdt; Bryan Van Meter; Orly Ardon; Matthew G Hanna; Dan Kelly; Chelsea Sowards; Michael Montalto; Marilyn Bui; Mark D Zarella; Victoria LaRosa; Gerard Slootweg; Juan Antonio Retamero; Mark C Lloyd; James Madory; Doug Bowman
Journal:  J Pathol Inform       Date:  2021-04-07

8.  Quantitative Image Analysis for Tissue Biomarker Use: A White Paper From the Digital Pathology Association.

Authors:  Haydee Lara; Zaibo Li; Esther Abels; Famke Aeffner; Marilyn M Bui; Ehab A ElGabry; Cleopatra Kozlowski; Michael C Montalto; Anil V Parwani; Mark D Zarella; Douglas Bowman; David Rimm; Liron Pantanowitz
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-08-01

Review 9.  Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

Authors:  Jan Hudeček; Leonie Voorwerk; Maartje van Seijen; Iris Nederlof; Michiel de Maaker; Jose van den Berg; Koen K van de Vijver; Karolina Sikorska; Sylvia Adams; Sandra Demaria; Giuseppe Viale; Torsten O Nielsen; Sunil S Badve; Stefan Michiels; William Fraser Symmans; Christos Sotiriou; David L Rimm; Stephen M Hewitt; Carsten Denkert; Sibylle Loibl; Sherene Loi; John M S Bartlett; Giancarlo Pruneri; Deborah A Dillon; Maggie C U Cheang; Andrew Tutt; Jacqueline A Hall; Zuzana Kos; Roberto Salgado; Marleen Kok; Hugo M Horlings
Journal:  NPJ Breast Cancer       Date:  2020-05-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.